These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34920978)

  • 1. Tumor immunology CRISPR screening: present, past, and future.
    Dong MB; Tang K; Zhou X; Zhou JJ; Chen S
    Trends Cancer; 2022 Mar; 8(3):210-225. PubMed ID: 34920978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogating immune cells and cancer with CRISPR-Cas9.
    Buquicchio FA; Satpathy AT
    Trends Immunol; 2021 May; 42(5):432-446. PubMed ID: 33812776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches.
    Ahmed MZ; Badani P; Reddy R; Mishra G
    J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Cancer Immunotherapy with CRISPR-Based Technology.
    Li Z; Fei T
    Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR technology for immuno-oncology applications.
    Wang J; Balan V; Marincola F
    Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.
    Liu Z; Shi M; Ren Y; Xu H; Weng S; Ning W; Ge X; Liu L; Guo C; Duo M; Li L; Li J; Han X
    Mol Cancer; 2023 Feb; 22(1):35. PubMed ID: 36797756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity.
    Wang YM; Wang HZ; Jian YZ; Luo ZT; Shao HW; Zhang WF
    Hum Gene Ther; 2022 Apr; 33(7-8):358-370. PubMed ID: 34963339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR Cas System: An efficient tool for cancer modelling.
    Akhtar M; Jamal T; Khan M; Khan SR; Haider S; Jalil F
    J Pak Med Assoc; 2021 Feb; 71(2(B)):718-724. PubMed ID: 33941966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR in cancer biology and therapy.
    Katti A; Diaz BJ; Caragine CM; Sanjana NE; Dow LE
    Nat Rev Cancer; 2022 May; 22(5):259-279. PubMed ID: 35194172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
    Cheng X; Fan S; Wen C; Du X
    Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
    Zhang X; Cheng C; Sun W; Wang H
    Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.